Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
CLL Society has put together a learning activity that will help those with CLL / SLL learn about the role of MRD testing, gain an understanding of how it can be used as part of your disease management plan, and empower you to discuss its potential use with your healthcare provider.
Flow cytometry is the standard test to look for Measurable (Minimal) Residual Disease (MRD) in CLL and it can find one cancer cell in 10,000 by looking at the telltale combination
In this 2019 iwCLL interview with Dr. Andy Rawstrom, we learn that he is a clinical scientist who helps with the diagnostics of many UK clinical trials. Dr. Rawstrom explains the value of MRD testing as a strong predictor of the future course of a patient’s CLL.
Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.
The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity and, in some cases, normal metabolic activity on PET-CT scans, several patients had persistently enlarged lymph nodes.
One click to our most popular content.
